Interviews
View More
The Future of Treatment Approaches for Pulmonary Fibrosis

An expert discusses the key unmet needs in current treatment approaches for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Treatment Algorithms and Insurance Coverage for Pulmonary Fibrosis

An expert discusses the treatment algorithm for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), along with insurance coverage for the available treatment options.

The Gut Microbiome’s Essential Role in IBD

Environmental factors like diet and early antibiotic use have an impact on the gut microbiome and can contribute to inflammatory bowel disease (IBD), explained Ashwin N. Ananthakrishnan, M.D., M.P.H., MGH, associate professor of medicine at Massachusetts General Hospital.

Tailoring Treatment for Narcolepsy

An expert discusses important considerations for clinicians when tailoring narcolepsy treatment plans for patients with complex comorbidities or lifestyle needs.

Fending Off Major Cuts May Be the Bigger Fight, But Medicaid Work Requirements Are Also a Bad Idea | Leanne Berge, J.D., CEO of Community Health Plan of Washington

Major Medicaid cuts may be overshadowing work requirements, but they remain a priority for Republicans. Work requirements are “bad health policy,” says Leanne Berge, J.D., CEO of the Community Health Plan of Washington, although they would not have as great an impact as the cuts that have been under discussion.

Addressing the Gap in Type 1 Diabetes Care with Personalized Coaching and Education

Arti Masturzo, M.D., chief medical officer of CCS, spoke with Managed Healthcare Executive about the differences in coaching and guiding patients with type 1 diabetes compared to type 2.

What ‘Going Wild’ on Healthcare Could Mean: The Early Days of Trump Healthcare

Three Washington, D.C., healthcare policy experts and the former chief of staff of HHS dive into the healthcare politics and policies of the new administration: RFK Jr.’s confirmation hearings; the future of IRA drug price negotiations and PBM reform; Medicare Advantage under the new administration; DOGE cuts at HHS; and ant-DEI and the social determinants of health.

Looking Ahead: Strategic Planning for Biosimilar Integration

A panelist discusses how their institution is proactively adapting their formulary review processes and infrastructure to handle the growing biosimilar pipeline, while anticipating increased competition will drive strategic shifts in contracting and necessitate more flexible approaches to formulary management in the coming years.

Unmet Needs in the Treatment Guidelines for Pulmonary Fibrosis

An expert discusses the gaps or outdated elements in the American Thoracic Society (ATS) guidelines that have been identified.

Official Media Partners

PBMI logo

Join the Community

an mjh life sciences brand

© 2022 MJH Life Sciences® and PBMI. All rights reserved.